Cointime

Elypta

company

About

Preventing cancer mortality by developing a metabolism-based liquid biopsy platform for early detection and monitoring

  • 11 - 50

Highlights

Total Funding Amount
$21M kr65M
Funding Rounds
2
Investors
2
Investments
1

Details

Last Funding Type
Series A
Last Funding Money Raised
$21M
Industries
Biotechnology,Health Care,Health Diagnostics
Founded date
May 1, 2017
Number Of Employee
11 - 50
Operating Status
Active

Elypta is developing a metabolism-based liquid biopsy platform based on a new IVD laboratory assay kit and artificial intelligence algorithms trained by their clinical database.
Elypta proudly sponsors the clinical trial series AURORAX to investigate applications in their lead indication renal cell carcinoma from surveillance of recurrence to monitoring treatment response. They also explore several other indications to understand the full potential for Elypta’s platform.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$21M kr65M
Elypta has raised a total of $21M kr65M in funding over 2 rounds. Their latest funding was raised on Jun 20, 2022 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jun 20, 2022 Series A $21M 2 — — Detail
Jan 23, 2020 Seed kr65M 1 — — Detail

Investments

Number of Investments
Number of Lead Investments
1
0
Elypta has made 1 investments. Their most recent investment was on Dec 16, 2015, when Springboard raised $1.70M.
Date Company Name
Round Money Raised Industry Lead Investor
Dec 16, 2015 Springboard
Seed $1.70M E-Learning —

Investors

Number of Lead Investors
Number of Investors
—
2
Elypta is funded by 2 investors. Hillclimber and Norrsken VC are the most recent investors.
Investor Name Lead Investor Funding Round
Hillclimber — Series A
Norrsken VC — Series A
Cointime
Content
Company